In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: Psoralen-based photochemical treatment step-by-step

Blood Transfusion

Volumn 13, Issue 2, 2015, Pages 255-264

  Abonnenc, Mélanie ^a   Sonego, Giona ^a   Kaiser Guignard, Julie ^a   Crettaz, David ^a   Prudent, Michel ^a   Tissot, Jean Daniel ^a   Lion, Niels ^a  

^a Vaudois Regional Blood Transfusion Service   (Switzerland)

Author keywords

Intercept blood system ^{< sup>; Pathogen reduction technology; Platelet storage lesion}

Indexed keywords

AMOTOSALEN; FIBRINOGEN; GLYCOPROTEIN IB ALPHA; NONOXINOL 9; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PSORALEN; THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD BUFFY COAT; CELL VIABILITY; ERYTHROCYTE; FLOW CYTOMETRY; HUMAN; ILLUMINATION; IN VITRO STUDY; LEUKOCYTE COUNT; MEMBRANE POTENTIAL; PHOTOCHEMISTRY; PROTEIN EXPRESSION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; ULTRAVIOLET RADIATION; BLOOD SAFETY; DISINFECTION; EVALUATION STUDY; FEMALE; MALE; PROCEDURES; THROMBOCYTE;

BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD SAFETY; DISINFECTION; FEMALE; FICUSIN; HUMANS; MALE; PHOTOCHEMICAL PROCESSES;

EID: 84927558924     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2014.0082-14     Document Type: Article

References (65)

1. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-26.
2. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124.
3. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
4. Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apher Sci 2012;46:221-9.
5. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
6. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000;78:209-16.
7. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45:580-90.
8. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005;15:269-76.
9. Jauvin V, Alfonso RD, Guillemain B, et al. In vitro photochemical inactivation of cell-associated human T-cell leukemia virus type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005;45:1151-9.
10. Sawyer L, Hanson D, Castro G, et al. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007;47:1062-70.
11. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496-504.
12. Brecher ME, Hay S, Corash L, et al. Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment. Transfusion 2007;47:1896-901.
13. Van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003;47:475-9.
14. Castro E, Girones N, Bueno JL, et al. The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007;47:434-41.
15. Grellier P, Benach J, Labaied M, et al. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008;48:1676-84.
16. Eastman RT, Barrett LK, Dupuis K, et al. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005;45:1459-63.
17. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-8.
18. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011;38:19-31.
19. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013;3:CD009072.
20. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
21. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012;102:302-16.
22. Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogenreduced platelets. Transfusion 2011;51:1058-71.
23. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012;103:322-30.
24. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008;94:315-23.
25. Osselaer JC, Doyen C, Defoin L, et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-22.
26. Cazenave JP, Isola H, Waller C, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011;51:622-9.
27. Sigle JP, Infanti L, Studt JD, et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion 2013;53:1788-97.
28. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gammairradiated single-donor platelet concentrates during long-term storage. Transfusion 2007;47:653-65.
29. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-9.
30. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79:206-14.
31. Jansen GA, van Vliet HH, Vermeij H, et al. Functional characteristics of photochemically treated platelets. Transfusion 2004;44:313-9.
32. Hechler B, Ohlmann P, Chafey P, et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013;53:1187-200.
33. Lozano M, Galan A, Mazzara R, et al. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007;47:666-71.
34. Prudent M, Crettaz D, Delobel J, et al. Proteomic analysis of Intercept-treated platelets. Journal of proteomics 2012;76 Spec No.:316-28.
35. Thiele T, Sablewski A, Iuga C, et al. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation - a LC-ESI-MS/MS-based proteomics approach. Blood Transfus 2012;10(Suppl 2):s63-70.
36. Prudent M, D'Alessandro A, Cazenave JP, et al. Proteome changes in platelets after pathogen inactivation - an interlaboratory consensus. Transfus Med Rev 2014;28:72-83.
37. Bellavite P, Andrioli G, Guzzo P, et al. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994;216:444-50.
38. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
39. Cardigan R, Turner C, Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005;88:153-63.
40. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009;97:26-33.
41. Picker SM, Schneider V, Oustianskaia L, Gathof BS. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009;49:2311-8.
42. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Annexin V release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction. Transfus Med Hemother 2010;37:7-12.
43. Chavarin P, Cognasse F, Argaud C, et al. In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood SystemTM). Vox Sang 2011;100:247-9.
44. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT blood system for platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86:239-45.
45. Wagner SJ, Skripchenko A, Myrup A, et al. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light. Transfusion 2009;49:704-10.
46. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arteriosclerosis, thrombosis, and vascular biology 2010;30:2341-9.
47. Offermanns S. Activation of platelet function through G proteincoupled receptors. Circulation research 2006;99:1293-304.
48. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008;28:403-12.
49. Ohto H, Nollet KE. Overview on platelet preservation: better controls over storage lesion. Transfus Apher Sci 2011;44:321-5.
50. Shrivastava M. The platelet storage lesion. Transfus Apher Sci 2009;41:105-13.
51. Miyaji R, Sakai M, Urano H, et al. Decreased platelet aggregation of platelet concentrate during storage recovers in the body after transfusion. Transfusion 2004;44:891-9.
52. Johnson L, Loh YS, Kwok M, Marks DC. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT blood system. Transfus Med 2013;23:121-9.
53. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010;11:288-300.
54. van Marwijk Kooy M, Akkerman JW, van Asbeck S., et al. UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species. Br J Haematol 1993;83:253-8.
55. Zhi L, Chi X, Gelderman MP, Vostal JG. Activation of platelet protein kinase C by ultraviolet light B mediates platelet transfusion-related acute lung injury in a two-event animal model. Transfusion 2013;53:722-31.
56. Verhaar R, Dekkers DW, De Cuyper IM, et al. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008;112:4935-9.
57. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998;38:31-40.
58. Leytin V. Apoptosis in the anucleate platelet. Blood Rev 2012;26:51-63.
59. Li J, Xia Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion 2000;40:1320-9.
60. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009;114:663-6.
61. Jobe SM, Wilson KM, Leo L, et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood 2008;111:1257-65.
62. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002;88:186-93.
63. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion 2003;43:526-35.
64. Leytin V, Allen DJ, Mutlu A, et al. Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage. Br J Haematol 2008;142:494-7.
65. Cookson P, Sutherland J, Turner C, et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus Med 2010;20:392-402.